The American Cancer Society

The American Cancer Society
Student’s Name
Institutional Affiliations

The American Cancer Society
The American Cancer Society provides educational support for patients diagnosed with cancer. The recommendations provided assists in the primary care of the patients as well as other clinicians care. Also, the patient undergoes the counseling with the primary care clinicians so as to maintain a healthy lifestyle. With education offered by the American Cancer Society, the patient is monitored for the post-treatment symptoms that may affect the effect the patient’s quality of life. I would recommend the guidelines offered by the ACS on the surveillance for the recurrence and the assessment which will help in the management of the psychological and physical effects which are long-term ADDIN CSL_CITATION {“citationItems”:[{“id”:”ITEM-1″,”itemData”:{“DOI”:”10.1200/JCO.2015.64.3809″,”ISBN”:”0007-9235″,”ISSN”:”15277755″,”PMID”:”26644543″,”abstract”:”The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline.

A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.”,”author”:[{“dropping-particle”:””,”family”:”Runowicz”,”given”:”Carolyn D.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Leach”,”given”:”Corinne R.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Henry”,”given”:”N. Lynn”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Henry”,”given”:”Karen S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Mackey”,”given”:”Heather T.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Cowens-Alvarado”,”given”:”Rebecca L.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Cannady”,”given”:”Rachel S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Pratt-Chapman”,”given”:”Mandi L.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Edge”,”given”:”Stephen B.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Jacobs”,”given”:”Linda A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Hurria”,”given”:”Arti”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Marks”,”given”:”Lawrence B.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”LaMonte”,”given”:”Samuel J.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Warner”,”given”:”Ellen”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Lyman”,”given”:”Gary H.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Ganz”,”given”:”Patricia A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””}],”container-title”:”Journal of Clinical Oncology”,”id”:”ITEM-1″,”issued”:{“date-parts”:[[“2016″]]},”title”:”American cancer society/American society of clinical oncology breast cancer survivorship care guideline”,”type”:”article-journal”},”uris”:[“http://www.mendeley.com/documents/?uuid=13774119-4174-460d-85f4-822dd86771c6″]}],”mendeley”:{“formattedCitation”:”(Runowicz et al., 2016)”,”plainTextFormattedCitation”:”(Runowicz et al., 2016)”,”previouslyFormattedCitation”:”(Runowicz et al., 2016)”},”properties”:{“noteIndex”:0},”schema”:”https://github.com/citation-style-language/schema/raw/master/csl-citation.json”}(Runowicz et al., 2016). As a result, the patient’s health is promoted, and the practice for a quality lifestyle is coordinated in the care.
Factors contributing to the high rate mortality of cancer in America, despite the advances of the American Cancer Society include the biological and sociocultural cultures associated with the health disparities. Also, the development of the ethical and racial entities has been found to be a factor contributing to the mortality rate of cancer increase in America. Another factor that contributes to the mortality rate of cancer in America is the poor prognosis. Increased smoking rates have also been found to raise the cancer mortality rate in America. The cancer incidents and mortality rates have been associated with the biological and genetic factors as well as the interaction with the environment.
Changes in policy and practices that could affect the figure over time are the commitment of the American Society of Cancer to resolve and reconcile the educational program. With the aim of preventing the increase in cancer mortality rates, the commercial support should embrace practices of solving the environmental and genetic pressure in the patients. As a result, there will be a reduced rate of cancer mortality in America ADDIN CSL_CITATION {“citationItems”:[{“id”:”ITEM-1″,”itemData”:{“DOI”:”10.1200/JCO.2015.64.3809″,”ISBN”:”0007-9235″,”ISSN”:”15277755″,”PMID”:”26644543″,”abstract”:”The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.”,”author”:[{“dropping-particle”:””,”family”:”Runowicz”,”given”:”Carolyn D.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Leach”,”given”:”Corinne R.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Henry”,”given”:”N. Lynn”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Henry”,”given”:”Karen S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Mackey”,”given”:”Heather T.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Cowens-Alvarado”,”given”:”Rebecca L.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Cannady”,”given”:”Rachel S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Pratt-Chapman”,”given”:”Mandi L.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Edge”,”given”:”Stephen B.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Jacobs”,”given”:”Linda A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Hurria”,”given”:”Arti”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Marks”,”given”:”Lawrence B.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”LaMonte”,”given”:”Samuel J.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Warner”,”given”:”Ellen”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Lyman”,”given”:”Gary H.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Ganz”,”given”:”Patricia A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””}],”container-title”:”Journal of Clinical Oncology”,”id”:”ITEM-1″,”issued”:{“date-parts”:[[“2016″]]},”title”:”American cancer society/American society of clinical oncology breast cancer survivorship care guideline”,”type”:”article-journal”},”uris”:[“http://www.mendeley.com/documents/?uuid=13774119-4174-460d-85f4-822dd86771c6″]}],”mendeley”:{“formattedCitation”:”(Runowicz et al., 2016)”,”plainTextFormattedCitation”:”(Runowicz et al., 2016)”,”previouslyFormattedCitation”:”(Runowicz et al., 2016)”},”properties”:{“noteIndex”:0},”schema”:”https://github.com/citation-style-language/schema/raw/master/csl-citation.json”}(Runowicz et al., 2016). The practices and policies of the patient diagnosed with cancer should be completed and apply the clinical activities required. The mediation of the factors contributing to the high mortality of cancer requires negative regulations of the growth and environmental factors.
A research program of the ACS in the field of clinical oncology contains a panel of experts of the medical oncology. This panel is responsible for undertaking a systematic review of cancer patients’ survivals. The program has both the adverse events and the progression-free survival means for patient suffering from cancer.
A research program of the American Cancer Society of the clinical oncology has an expert panel of medical oncology that have a systematic review of the survival of the cancer patients. The program has the progression-free survival means and adverse events for the cancer patients. Its goal of caring, as well as the preference of the patient, is considered in the program for the treatment purpose and psychological status. Therefore, the program guides the decision for treatment with the symptom burdens with the availability of the support based on the preferences of the patient ADDIN CSL_CITATION {“citationItems”:[{“id”:”ITEM-1″,”itemData”:{“DOI”:”10.1200/JCO.2016.67.1412″,”ISBN”:”1527-7755 (Electronic)\r0732-183X (Linking)”,”ISSN”:”15277755″,”PMID”:”27247216″,”abstract”:”Purpose To provide evidence-based recommendations to oncologists and others for the treatment of patients with metastatic pancreatic cancer. Methods American Society of Clinical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology, palliative care, and advocacy experts to conduct a systematic review of the literature from April 2004 to June 2015. Outcomes were overall survival, disease-free survival, progression-free survival, and adverse events. Results Twenty-four randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the chest, abdomen, and pelvis should be performed. Baseline performance status and comorbidity profile should be evaluated. Goals of care, patient preferences, treatment response, psychological status, support systems, and symptom burden should guide decisions for treatments. A palliative care referral should occur at first visit. FOL-FIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable comorbidity profile) or gemcitabine plus nanoparticle albumin-bound (NAB) -paclitaxel (adequate comorbidity profile) should be offered to patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1 based on patient preference and support system available. Gemcitabine alone is rec-ommended for patients with ECOG PS 2 or with a comorbidity profile that precludes other regimens; the addition of capecitabine or erlotinib may be offered. Patients with an ECOG PS $ 3 and poorly controlled comorbid conditions should be offered cancer-directed therapy only on a case-by-case basis; supportive care should be emphasized. For second-line therapy, gemcitabine plus NAB-paclitaxel should be offered to patients with first-line treatment with FOLFIRINOX, an ECOG PS 0 to 1, and a favorable comorbidity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxel, ECOG PS 0 to 1, and favorable comorbidity profile, and gemcitabine or fluorouracil should be offered to patients with either an ECOG PS 2 or a comorbidity profile that precludes other regimens. Additional information is available at www.asco.org/guidelines/MetPC and www.asco. org/guidelineswiki.”,”author”:[{“dropping-particle”:””,”family”:”Sohal”,”given”:”Davendra P.S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Mangu”,”given”:”Pamela B.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Khorana”,”given”:”Alok A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Shah”,”given”:”Manish A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Philip”,”given”:”Philip A.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”O’Reilly”,”given”:”Eileen M.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Uronis”,”given”:”Hope E.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Ramanathan”,”given”:”Ramesh K.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Crane”,”given”:”Christopher H.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Engebretson”,”given”:”Anitra”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Ruggiero”,”given”:”Joseph T.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Copur”,”given”:”Mehmet S.”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Lau”,”given”:”Michelle”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Urba”,”given”:”Susan”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””},{“dropping-particle”:””,”family”:”Laheru”,”given”:”Daniel”,”non-dropping-particle”:””,”parse-names”:false,”suffix”:””}],”container-title”:”Journal of Clinical Oncology”,”id”:”ITEM-1″,”issued”:{“date-parts”:[[“2016″]]},”title”:”Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline”,”type”:”article”},”uris”:[“http://www.mendeley.com/documents/?uuid=f21b6fbf-69a8-41d5-9abd-adf98b83ddb1″]}],”mendeley”:{“formattedCitation”:”(Sohal et al., 2016)”,”plainTextFormattedCitation”:”(Sohal et al., 2016)”,”previouslyFormattedCitation”:”(Sohal et al., 2016)”},”properties”:{“noteIndex”:0},”schema”:”https://github.com/citation-style-language/schema/raw/master/csl-citation.json”}(Sohal et al., 2016). The supportive care and the patients control emphasis offer the patient the first line treatment that favors his or her profile.
The American Cancer Society has a great impact on the prevention and treatment of cancer since it makes a difference in the patient’s life by improving cancer care. Due to the commitment of the professional oncology society program, the research offers the quality of patient care for the prevention and treatment of cancer. The commitment of the American Cancer Society gives the patient the cancer care with the developed program that fosters the working knowledge and environment of the patient. Also, the program has favorable cancer prevention treatment resources that are cost-effective and influences cancer care with a comprehensive approach that promotes cancer awareness and education. As a result, the clinical practices are improved hence best and quality delivery of cancer care.

References
ADDIN Mendeley Bibliography CSL_BIBLIOGRAPHY Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., … Ganz, P. A. (2016). American cancer society/American society of clinical oncology breast cancer survivorship care guideline. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2015.64.3809
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O’Reilly, E. M., … Laheru, D. (2016). Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2016.67.1412